These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27025318)

  • 21. Changes in body composition during androgen deprivation therapy for prostate cancer.
    Smith MR; Finkelstein JS; McGovern FJ; Zietman AL; Fallon MA; Schoenfeld DA; Kantoff PW
    J Clin Endocrinol Metab; 2002 Feb; 87(2):599-603. PubMed ID: 11836291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer.
    Sweeney CJ
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):588-90. PubMed ID: 17111557
    [No Abstract]   [Full Text] [Related]  

  • 23. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
    Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
    Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.
    Têtu B
    Can J Oncol; 1994 Nov; 4 Suppl 1():33-4; discussion 35-6. PubMed ID: 8853487
    [No Abstract]   [Full Text] [Related]  

  • 25. Prostate cancer therapy: going forwards by going backwards.
    Sweeney C
    Lancet Oncol; 2013 Feb; 14(2):104-5. PubMed ID: 23306099
    [No Abstract]   [Full Text] [Related]  

  • 26. [Combined treatment of metastatic hormone-resistant prostate cancer].
    Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
    Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
    [No Abstract]   [Full Text] [Related]  

  • 27. Androgen deprivation therapy and prostate cancer duration.
    Williams SG; Pickles T; Buyyounouski MK
    J Clin Oncol; 2009 Dec; 27(34):e228; author reply e229. PubMed ID: 19884533
    [No Abstract]   [Full Text] [Related]  

  • 28. Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
    Cai T; Bartoletti R
    J Clin Oncol; 2007 Aug; 25(22):3385; author reply 3385-6. PubMed ID: 17664492
    [No Abstract]   [Full Text] [Related]  

  • 29. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
    Diamond T; Campbell J; Bryant C; Lynch W
    Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intermittent versus continuous androgen deprivation treatment of prostate cancer.
    Zhu J; Zheng Y
    J Clin Oncol; 2013 Nov; 31(31):4024. PubMed ID: 24062402
    [No Abstract]   [Full Text] [Related]  

  • 31. Prostate cancer--management of disseminated disease (intermittent androgen suppression).
    Lobel B; Richard F
    Acta Chir Iugosl; 2005; 52(4):11-2. PubMed ID: 16673586
    [No Abstract]   [Full Text] [Related]  

  • 32. [The question of intermittent hormonal treatment of cancer of the prostate].
    Boca P
    Acta Urol Belg; 1998 May; 66(2):17-20. PubMed ID: 9633121
    [No Abstract]   [Full Text] [Related]  

  • 33. Prostate cancer: Testosterone-guided ADT for prostate cancer.
    Nishiyama T; Hoshii T
    Nat Rev Urol; 2016 Apr; 13(4):189-91. PubMed ID: 26813950
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
    Taneja SS
    J Urol; 2013 Dec; 190(6):2094. PubMed ID: 24209521
    [No Abstract]   [Full Text] [Related]  

  • 35. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
    Altundag K; Altundag O; Morandi P; Gunduz M
    Urology; 2005 Jan; 65(1):211-2; author reply 212. PubMed ID: 15667906
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Penson DF
    J Urol; 2016 Feb; 195(2):353. PubMed ID: 26852977
    [No Abstract]   [Full Text] [Related]  

  • 37. Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: pitfalls of its use as an early surrogate marker for bone metastasis.
    Moseshvili E; Joseph DJ; Spry NA; Cohen RJ; Abreu A; Kautto A; Denham JW
    J Med Imaging Radiat Oncol; 2014 Aug; 58(4):497-502. PubMed ID: 24418365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of intermittent androgen deprivation in prostate cancer.
    Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
    BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
    [No Abstract]   [Full Text] [Related]  

  • 39. Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Garnick MB
    BJU Int; 2012 Oct; 110(8):1155. PubMed ID: 22369480
    [No Abstract]   [Full Text] [Related]  

  • 40. Prolonging survival in prostate cancer: chemotherapy will have an important role.
    Parker C; Emberton M
    BJU Int; 2005 Jul; 96(1):2-3. PubMed ID: 15963108
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.